ABBOTT LABORATORIES — Major Shareholding Notification 2010

Sep 27, 2010

SC 13G 1 a10-18164_1sc13g.htm SC 13G

| UNITED
STATES |
| --- |
| SECURITIES
AND EXCHANGE COMMISSION |
| Washington,
D.C. 20549 |

*SCHEDULE 13G*

*Under the Securities Exchange Act of 1934 (Amendment No. )**

*Trubion Pharmaceuticals, Inc.*

(Name of Issuer)

*Common Stock, par value $0.001 per share*

(Title of Class of Securities)

*89778N102*

(CUSIP Number)

*September 27, 2010*

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o	Rule 13d-1(b)
x	Rule 13d-1(c)
o	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

SEQ.=1,FOLIO='',FILE='C:\JMS\105627\10-18164-1\task4283641\18164-1-ba.htm',USER='105627',CD='Sep 27 22:04 2010'

*13G*

CUSIP No. 89778N102 — 1	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only) Abbott Laboratories
2	Check the Appropriate Box
if a Member of a Group (See Instructions)
	(a)	o
	(b)	o
3	SEC Use Only
4	Citizenship or Place of
Organization Illinois
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 2,243,649
	6	Shared Voting Power 0
	7	Sole Dispositive Power 2,243,649
	8	Shared Dispositive Power 0
9	Aggregate Amount
Beneficially Owned by Each Reporting Person 2,243,649
10	Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions) o
11	Percent of Class
Represented by Amount in Row (9) 10.99%
12	Type of Reporting Person
(See Instructions) CO

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105627\10-18164-1\task4283641\18164-1-ba.htm',USER='105627',CD='Sep 27 22:04 2010'

Item 1.	(a)	Name of Issuer: Trubion Pharmaceuticals, Inc.
	(b)	Address of Issuer’s
Principal Executive Offices: 2401 Fourth Avenue, Suite 1050 Seattle, WA 98121
Item 2.
	(a)	Name of Person Filing: Abbott Laboratories
	(b)	Address of Principal
Business Office, or if none, Residence: 100 Abbott Park Road Abbott Park, Illinois
60064-6400
	(c)	Citizenship: Illinois
	(d)	Title of Class of
Securities: Common Stock, par value $0.001 per share
	(e)	CUSIP Number: 89778N102
Item 3.	If this statement is filed pursuant
to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
	(a)	o	Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o);
	(b)	o	Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
	(c)	o	Insurance company as
defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d)	o	Investment
company registered under section 8 of the Investment Company Act of 1940
(15 U.S.C. 80a-8);
	(e)	o	An
investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
	(f)	o	An
employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
	(g)	o	A
parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
	(h)	o	A
savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
	(i)	o	A
church plan that is excluded from the definition of an investment company
under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.
80a-3); or
	(j)	o	Group,
in accordance with Rule 13d-1(b)(1)(ii)(J).

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105627\10-18164-1\task4283641\18164-1-ba.htm',USER='105627',CD='Sep 27 22:04 2010'

| Item 4. | Ownership. — (a) | Amount beneficially
owned: 2,243,649
shares | |
| --- | --- | --- | --- |
| | (b) | Percent of class: 10.99% | |
| | (c) | Number
of shares as to which the reporting person has: | |
| | | (i) | Sole
power to direct the vote: 2,243,649 |
| | | (ii) | Shared
power to vote or direct the vote: 0 |
| | | (iii) | Sole
power to dispose or direct the disposition of: 2,243,649 |
| | | (iv) | Shared
power to dispose or direct the disposition of: 0 |
| Facet Biotech Corporation, a Delaware Corporation
(the “Company”), was acquired by Abbott Laboratories, an Illinois corporation
(“Abbott”), pursuant to a transaction that was completed on April 21,
2010 (the “Acquisition”). Following the Acquisition, the Company’s name was
changed to Abbott Biotherapeutics Corp.
In connection with the integration of the Company into Abbott
following the Acquisition, on September 27, 2010, the Company
transferred beneficial ownership of all 2,243,649 shares of common stock, par
value $0.001 of Trubion Pharmaceuticals, Inc. previously acquired by the
Company as reported on Schedule 13G filed by the Company on September 9,
2009, to Abbott. | | | |
| Item 5. | Ownership of Five Percent or Less
of a Class. | | |
| If this statement is
being filed to report the fact that as of the date hereof the reporting
person has ceased to be the beneficial owner of more than five percent of the
class of securities, check the following: o | | | |
| Item 6. | Ownership of More than Five Percent
on Behalf of Another Person. | | |
| | Not applicable. | | |
| Item 7. | Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent
Holding Company. | | |
| | Not
applicable. | | |
| Item 8. | Identification and Classification
of Members of the Group. | | |
| | Not
applicable. | | |
| Item 9. | Notice of Dissolution of Group. | | |
| | Not
applicable. | | |
| Item 10. | Certifications. | | |

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105627\10-18164-1\task4283641\18164-1-ba.htm',USER='105627',CD='Sep 27 22:04 2010'

*SIGNATURE*

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

| Date: September 27,
2010 | |
| --- | --- |
| ABBOTT LABORATORIES | |
| By: | /s/ Thomas C. Freyman |
| Name: | Thomas C. Freyman |
| Its: | Executive Vice President, Finance and Chief Financial Officer |

5

SEQ.=1,FOLIO='5',FILE='C:\JMS\105627\10-18164-1\task4283641\18164-1-ba.htm',USER='105627',CD='Sep 27 22:04 2010'